Provention Bio Inc Investor Relations Material

Provention Bio, Inc. is a clinical stage biopharmaceutical company that focuses on the development and commercialization of therapeutics and vaccines to intercept and prevent immune-mediated diseases. PRV-031 teplizumab, used to intercept the development of type one diabetes (T1D), was in Phase III clinical trial. PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus, is under preclinical development. Its products candidates include PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease.